SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
How heart failure risk rises after surgery
Wed June 29th - The development of atrial fibrillation following surgery is an important risk factor for heart failure, researchers report today. More
Brain surgery benefits intracranial pressure
Wed June 29th - Craniectomy for intracranial hypertension offers significant benefit, according to new guidance, triggered by British research. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Monoclonal antibody offers migraine hope

Wednesday April 18th, 2018

A monoclonal antibody offers a promising treatment for migraine, German researchers are to tell a major conference.

The researchers investigated a new drug called erenumab, which blocks pain by targeting a receptor for a compound that transmits pain signals.

The study involved 246 people who had episodic migraine and had not responded well to other medications. They were given injections of either 140 milligrams of erenumab or a placebo, monthly for three months.

At the end of the study period, those taking erenumab were nearly three times more likely to have reduced their migraine days by at least 50% than those on placebo. In the drug group, 30% reached this target, compared to 14% on placebo.

Those on the drug had an average 1.6 times greater reduction in migraine days and a 1.7 times greater reduction in acute medication days than those on placebo. The drug was deemed safe and tolerable.

Dr Uwe Reuter, of Charité - University Medicine Berlin, will present the findings at the upcoming American Academy of Neurology's 70th Annual Meeting in Los Angeles, USA.

He says: "The people we included in our study were considered more difficult to treat, meaning that up to four other preventative treatments hadn't worked for them.

"Our study found that erenumab reduced the average number of monthly migraine headaches by more than 50% for nearly a third of study participants. That reduction in migraine headache frequency can greatly improve a person's quality of life."

Results presented at the American Academy of Neurology's 70th Annual Meeting in Los Angeles, April 21 to 27, 2018.

Tags: Brain & Neurology | Europe | Pharmaceuticals

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES